Stockholm, Sweden, October 31, 2017 – BioArctic AB (publ) (“BioArctic” or the “Company” ) today announced that the number of shares and votes in BioArctic has increased during the month of October due to the new share issue carried out in connection with the listing of BioArctic’s B-share on Nasdaq Stockholm. A total of 25,000,000 B-shares have been added.
At October 31, 2017 the number of A-shares, each representing ten (10) votes, amounts to 14,399,996 and the number of B-shares, each representing one (1) vote, amounts to 73,659,989. The total number of votes thus amounts to 217,659,949.
BioArctic has no holding of own shares.
For more information, please contact:
Jan Mattsson, CFO
Phone: + 46 (0)70 352 27 72
Christina Astrén, Head IR & Communications
Phone: + 46 (0)70 835 43 36
This information is such that BioArctic is required to publish under the Swedish Financial Instruments Trading Act. The information was released for public disclosure, through the agency of the contact persons above, at 6.00 p.m. (CET) on October 31, 2017.
BioArctic AB (publ) is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). www.bioarctic.com